Revitope Oncology develops a novel immunotherapy platform—APEC—that uses tumor-targeting antibodies to selectively deliver viral antigens to cancer cells so existing virus-specific T cells recognize and kill tumor cells. The platform was born from research initiated in 2010 by Dr. Mark Cobbold at the University of Birmingham and a UK subsidiary was launched in 2014 to continue development. The company is led by president and CEO Julie M. Cherrington and its board includes Mark Cobbold, Peter M. Joost, Raj Mehta and Andrew Allen. Revitope plans to deploy the APEC platform to develop multiple compounds for the treatment of solid tumors and hematologic malignancies. The company raised $8.5M in funding to continue development of its platform and pipeline. No operating metrics (revenue/users) are disclosed in the article.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2016